Research Papers:

Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer

Giovanny Rodríguez-Blanco, Lona Zeneyedpour, Diederick Duijvesz, A. Marije Hoogland, Esther I. Verhoef, Charlotte F. Kweldam, Peter C. Burgers, Peter Sillevis Smitt, Chris H. Bangma, Guido Jenster, Geert J.L.H. van Leenders, Lennard J.M. Dekker and Theo M. Luider _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:36444-36456. https://doi.org/10.18632/oncotarget.26342

Metrics: PDF 1679 views  |   HTML 2256 views  |   ?  


Giovanny Rodríguez-Blanco1,*, Lona Zeneyedpour1,*, Diederick Duijvesz2,*, A. Marije Hoogland3, Esther I. Verhoef3, Charlotte F. Kweldam3, Peter C. Burgers1, Peter Sillevis Smitt1, Chris H. Bangma2, Guido Jenster2, Geert J.L.H. van Leenders3, Lennard J.M. Dekker1 and Theo M. Luider1

1Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands

2Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands

3Department of Pathology, Erasmus Medical Centre, Rotterdam, The Netherlands

*These authors have contributed equally to this work

Correspondence to:

Theo M. Luider, email: [email protected]

Keywords: prostate cancer; mass spectrometry; arachidonic acid

Received: August 13, 2018     Accepted: October 21, 2018     Published: November 23, 2018


Although many patients are cured from prostate cancer (PCa) by surgery only, there are still patients who will experience rising prostate-specific antigen (PSA) levels after surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic markers in PCa tissue might enable finding better treatment for those patients experiencing BCR with a high chance of metastasis. In this study, we aimed to identify altered proteins in prostate cancer tissue, and to evaluate their potential role as prognostic markers. We used two proteomics strategies to analyse 34 prostate tumours (PCa) and 33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic markers of the disease. Tissue microarray immunohistochemical staining indicated that a low percentage of positive tumour cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93)), and a low percentage of positive tumour cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-5.22)) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value for PCa.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26342